AR049419A1 - Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo - Google Patents
Hidroxi-6-fenilfenantridinas sustituidas con heterocicliloInfo
- Publication number
- AR049419A1 AR049419A1 ARP050100781A ARP050100781A AR049419A1 AR 049419 A1 AR049419 A1 AR 049419A1 AR P050100781 A ARP050100781 A AR P050100781A AR P050100781 A ARP050100781 A AR P050100781A AR 049419 A1 AR049419 A1 AR 049419A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- completely
- substituted
- heterocyclic ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Compuestos de la formula (1) en la cual: R1 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquil C3-7-metoxi, 2,2-difluoroetoxi, o alcoxi C1-4 completamente o predominantemente sustituido con F; R2 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquil C3-7-metoxi, 2,2-difluoroetoxi, o alcoxi C1-4 completamente o predominantemente sustituido con F; o en la cual R1 y R2 juntos son un grupo alquilendioxi C1-2; R3 es H o alquilo C1-4; R31 es H o alquilo C1-4; y en una primera realizacion (realizacion a) de acuerdo con la presente, R4 es -O-R41, en donde R41 es H, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxialquilo C2-4, alquil C1-7-carbonilo o alquilo C1-4 completamente o predominantemente sustituido por F, y R5 es H o alquilo C1-4; o, en una segunda realizacion (realizacion b) de acuerdo con la presente, R4 es H o alquilo C1-4 y R5 es -O-R51, en donde R51 es H, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxialquilo C2-4, alquil C1-7-carbonilo o alquilo C1-4 completamente o predominantemente sustituido con F; R6 es H, halogeno, alquilo C1-4 o alcoxi C1-4; R7 es Het1, Het2, Har1, Het3 o Har2, en donde Het1 está sustituido opcionalmente con R71 y es un radical de anillo heterocíclico completamente saturado, de 3 a 7 miembros, monocíclico, que comprende uno a tres heteroátomos seleccionados independientemente del grupo que consiste de N, O y S, en donde R71 es alquilo C1-4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Het2 está opcionalmente sustituido con R72 y es un radical de anillo heterocíclico, saturado o insaturado, de 5 a 7 miembros, monocíclico, que comprende un átomo de N y opcionalmente uno o dos heteroátomos adicionales seleccionados independientemente del grupo que consiste de N, O y S y a cuyo anillo están ligados uno o dos sustituyentes oxo, en donde R72 es alquilo C1-4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Har1 está opcionalmente sustituido con R73 y es un radical de anillo heterocíclico completamente insaturado, de 5 miembros, monocíclico, que comprende uno a cuatro heteroátomos seleccionados independientemente del grupo que consiste de N, O y S, en donde R73 es alquilo C1- 4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Het3 está opcionalmente sustituido con R74 y es un radical de anillo heterocíclico parcialmente insaturado, de 5 o 6 miembros, monocíclico, que comprende un átomo de N y opcionalmente un heteroátomo adicional seleccionado del grupo que consiste de N, O y S, en donde R74 es alquilo C1-4, alcoxi C1-4 o alquilo C1-4 completamente o parcialmente sustituido con F; Har2 está opcionalmente sustituido con R75 y/o R76 y significa un radical de anillo heterocíclico completamente insaturado, de 6 miembros, monocíclico, que comprende uno a tres átomos de N, en donde R75 es alquilo C1-4, alcoxi C1-4, alquiltio C1-4, halogeno, hidroxilo, amino, mono- o dialquil C1-4- amino, o alquilo C1-4 completamente o parcialmente sustituido con F; R76 es alcoxi C1-4, alquiltio C1-4, hidroxilo, amino o mono- o dialquil C1-4-amino, y las sales, los N-oxidos y las sales de los N-oxidos de estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04005005 | 2004-03-03 | ||
EP04106372 | 2004-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049419A1 true AR049419A1 (es) | 2006-08-02 |
Family
ID=34961674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100781A AR049419A1 (es) | 2004-03-03 | 2005-03-02 | Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070191413A1 (es) |
EP (1) | EP1812400A1 (es) |
JP (1) | JP2007526284A (es) |
KR (1) | KR20060130684A (es) |
AR (1) | AR049419A1 (es) |
AU (1) | AU2005223370A1 (es) |
BR (1) | BRPI0508256A (es) |
CA (1) | CA2557730A1 (es) |
IL (1) | IL177301A0 (es) |
NO (1) | NO20064220L (es) |
NZ (1) | NZ549109A (es) |
TW (1) | TW200540157A (es) |
WO (1) | WO2005090311A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003273805B8 (en) | 2002-08-29 | 2010-06-17 | Takeda Gmbh | 3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
DE60310576T2 (de) * | 2002-08-29 | 2007-10-31 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
CA2556086C (en) | 2004-02-18 | 2014-04-01 | Altana Pharma Ag | Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors |
ES2505473T3 (es) | 2004-03-03 | 2014-10-10 | Takeda Gmbh | Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la PDE4 |
KR20060130697A (ko) * | 2004-03-10 | 2006-12-19 | 알타나 파마 아게 | 신규한 아미도-치환 히드록시-6-페닐페난트리딘 및 pde4억제제로서의 이의 용도 |
US7718668B2 (en) | 2005-03-02 | 2010-05-18 | Nycomed Gmbh | Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives |
WO2009043784A1 (en) | 2007-10-04 | 2009-04-09 | F. Hoffmann-La Roche Ag | Cyclopropyl aryl amide derivatives and uses thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0916346A3 (en) * | 1991-09-20 | 2000-12-06 | Glaxo Group Limited | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
DK0882021T3 (da) * | 1996-01-31 | 2003-06-23 | Altana Pharma Ag | Nye phenanthridiner |
US6127378A (en) * | 1996-03-26 | 2000-10-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines substituted in the 6 position |
EA001551B1 (ru) * | 1996-11-11 | 2001-04-23 | Бык Гюльден Ломберг Хемише Фабрик Гмбх | Бензонафтиридины в качестве бронхиальных терапевтических средств |
AU756349B2 (en) * | 1997-07-25 | 2003-01-09 | Altana Pharma Ag | Substituted 6-phenylphenanthridines |
DE69822162T2 (de) * | 1997-07-25 | 2005-01-27 | Altana Pharma Ag | Neue tetrazolderivate |
ATE224372T1 (de) * | 1997-07-25 | 2002-10-15 | Altana Pharma Ag | Substituierte 6-alkylphenanthridine |
PT1075477E (pt) * | 1998-05-05 | 2003-07-31 | Altana Pharma Ag | Novos n-oxidos de benzonaftiridina |
DE60024581T2 (de) * | 1999-01-15 | 2006-08-10 | Altana Pharma Ag | 6-phenylphenanthridine mit pde-iv hemmender wirkung |
CA2359404A1 (en) * | 1999-01-15 | 2000-07-20 | Beate Gutterer | Phenanthridine-n-oxides with pde-iv inhibiting activity |
DK1147103T3 (da) * | 1999-01-15 | 2005-08-29 | Altana Pharma Ag | Phenanthridin-N-oxider med PDE-IV-inhiberende aktivitet |
ES2236288T3 (es) * | 2000-07-14 | 2005-07-16 | Altana Pharma Ag | 6-heteroarilfenantridinas. |
DK1377574T3 (da) * | 2001-02-21 | 2005-04-25 | Altana Pharma Ag | 6-phenylbenzonaphtyridiner |
WO2004018431A2 (en) * | 2002-08-17 | 2004-03-04 | Altana Pharma Ag | Novel phenanthridines |
AU2003273805B8 (en) * | 2002-08-29 | 2010-06-17 | Takeda Gmbh | 3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
DE60310576T2 (de) * | 2002-08-29 | 2007-10-31 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
AU2003277069A1 (en) * | 2002-09-30 | 2004-04-23 | Ciphergen Biosystems, Inc. | Apparatus and method for expression and capture of biomolecules and complexes on adsorbent surfaces |
CA2556086C (en) * | 2004-02-18 | 2014-04-01 | Altana Pharma Ag | Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors |
KR20060124784A (ko) * | 2004-03-09 | 2006-12-05 | 알타나 파마 아게 | 신규한 이소아미도 치환된 히드록시-6-페닐페난트리딘 및pde4 억제제로서의 이의 용도 |
CA2558390A1 (en) * | 2004-03-10 | 2005-09-22 | Altana Pharma Ag | Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
KR20060130697A (ko) * | 2004-03-10 | 2006-12-19 | 알타나 파마 아게 | 신규한 아미도-치환 히드록시-6-페닐페난트리딘 및 pde4억제제로서의 이의 용도 |
WO2005085203A1 (en) * | 2004-03-10 | 2005-09-15 | Altana Pharma Ag | Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
US20080119505A1 (en) * | 2005-02-01 | 2008-05-22 | Altana Pharma Ag | Novel 6-Pyridylphenanthridines |
US20080167316A1 (en) * | 2005-03-02 | 2008-07-10 | Altana Pharma Ag | 6-Heteroaryl-1,2,3,4,4A, 10B-Hexahydrophenanthridines as Pde4-Inhibitors for the Treatment of Inflammatory Disorders |
AU2006221957A1 (en) * | 2005-03-09 | 2006-09-14 | Nycomed Gmbh | Amido-substituted 6-phenylphenanthridines |
US20070161019A1 (en) * | 2005-11-04 | 2007-07-12 | Johji Inazawa | Method for detecting cancer and a method for suppressing cancer |
-
2005
- 2005-03-02 AR ARP050100781A patent/AR049419A1/es unknown
- 2005-03-03 NZ NZ549109A patent/NZ549109A/en unknown
- 2005-03-03 US US10/590,805 patent/US20070191413A1/en not_active Abandoned
- 2005-03-03 TW TW094106491A patent/TW200540157A/zh unknown
- 2005-03-03 CA CA002557730A patent/CA2557730A1/en not_active Abandoned
- 2005-03-03 AU AU2005223370A patent/AU2005223370A1/en not_active Abandoned
- 2005-03-03 EP EP05716896A patent/EP1812400A1/en not_active Withdrawn
- 2005-03-03 WO PCT/EP2005/050946 patent/WO2005090311A1/en active Application Filing
- 2005-03-03 JP JP2007501292A patent/JP2007526284A/ja not_active Withdrawn
- 2005-03-03 KR KR1020067019918A patent/KR20060130684A/ko not_active Application Discontinuation
- 2005-03-03 BR BRPI0508256-0A patent/BRPI0508256A/pt not_active IP Right Cessation
-
2006
- 2006-08-06 IL IL177301A patent/IL177301A0/en unknown
- 2006-09-18 NO NO20064220A patent/NO20064220L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007526284A (ja) | 2007-09-13 |
US20070191413A1 (en) | 2007-08-16 |
NO20064220L (no) | 2006-09-18 |
KR20060130684A (ko) | 2006-12-19 |
BRPI0508256A (pt) | 2007-07-31 |
WO2005090311A1 (en) | 2005-09-29 |
TW200540157A (en) | 2005-12-16 |
NZ549109A (en) | 2010-05-28 |
EP1812400A1 (en) | 2007-08-01 |
CA2557730A1 (en) | 2005-09-29 |
AU2005223370A1 (en) | 2005-09-29 |
WO2005090311A8 (en) | 2006-10-26 |
IL177301A0 (en) | 2006-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049319A1 (es) | Derivados de 6-heteroarilfenantridinas | |
AR052913A1 (es) | Pirazolopirimidinas | |
CO6160322A2 (es) | Derivados de quinazolinona e isoquinolinona acetamida | |
PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
ES2722409T3 (es) | Moduladores de ROR gamma (RORy) | |
AR058896A1 (es) | Isoxazolinas para controlar plagas de invertebrados | |
PE20211698A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
CO6160315A2 (es) | Agonistas de piridona del receptor acoplado a proteina g gpr119 | |
PE20171240A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR043434A1 (es) | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos | |
AR060401A1 (es) | Derivados de cromen-2-ona | |
AR054262A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
AR077507A1 (es) | Derivados de naftiridina-1-ona y composiciones farmaceuticas que los comprenden como inhibidores de cinasa syk | |
AR048427A1 (es) | Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas. | |
AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
PE20190968A1 (es) | Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |